CONTINUING EDUCATION :: ANTIBODIES


Vitro Diagnostics EUAs — Serology and other adaptive immune response tests for SARS- CoV-2. https://www.fda.gov/medical-devices/ coronavirus-disease-2019-covid-19-emergency- use-authorizations-medical-devices/in-vitro- diagnostics-euas-serology-and-other-adaptive- immune-response-tests-sars-cov-2. Accessed October 13, 2021.


25. Bai Z, Cao Y, Liu W, Li J. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. Viruses. 2021; 13(6):1115. https://doi.org/10.3390/v13061115.


26. Mittal A, Manjunath K, Ranjan RK, Kaushik S, Kumar S, Verma V (2020) COVID-19 pandemic: Insights into structure, function, and hACE2 recep- tor recognition by SARS-CoV-2. PLoS Pathog 16(8): e1008762.


27. Okba N, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Anti- body Responses in Coronavirus Disease Patients. Emerging Infectious Diseases. 2020;26(7):1478-1488. doi:10.3201/eid2607.200841. doi: 10.1371/journal. ppat.1008762.


28. Suthar M, Zimmerman M, Kauffman R, Ahmed R, Rodback J, et al. Rapid generation of neutral- izing antibody responses in COVID-19 patients. Cell Rep Med. 2020 Jun 23;1(3):100040. doi: 10.1016/j. xcrm.2020.100040.


29. Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 2020;5(48):eabc8413. doi:


10.1126/sciimmunol.abc8413.


30. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA authorizes additional mono- clonal antibody for treatment of COVID-19. https:// www.fda.gov/news-events/press-announcements/ coronavirus-covid-19-update-fda-authorizes-addi- tional-monoclonal-antibody-treatment-covid-19. Updated May 26, 2021. Accessed: October 13, 2021.


31. McInstosh, K. COVID-19: epidemiology, virology, and prevention. UpToDate. uptodate. com/contents/covid-19-epidemiology-virology- and-prevention?search=tmab%20for%20 covid-19%20prevention&source=search_result& selectedTitle=3~150&usage_type=default&display_ rank=3#H1473330622. Revised October 6, 2021. Accessed October 29, 2021.


32. U.S. Food and Drug Administration. Fact sheet for health care providers emergency use authoriza- tion (EUA) of REGEN-COV. Last Revised: 09/17/2021. https://www.fda.gov/media/145611/download. Revised September 17, 2021. October 29, 2021.


33. National Institutes of Health. : ovid Treatment Guidelines: https://www.covid19treatmentguide- lines.nih.gov/about-the-guidelines/whats-new/. Updated October 27, 2021. Accessed October 13, 2021.


34. Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650- 655. doi:10.1126/science.abc6952.


35. Heffernan E, Hannan MM, Fitzgibbon M (2021) The role of SARS-Cov-2 antibody testing; current and future applications. J Infect Dis Ther. 9(4):466. doi: 10.4172/2332-0877.1000466


36. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-4428. doi:10.1016/j.vaccine.2021.05.063.


37. LifeBridge Health. Research on rapid test to detect COVID-19 antibody levels. News Wise. August 18, 2021. https://www.newswise.com/ coronavirus/research-on-rapid-test-to-detect- covid-19-antibody-levels/?article_id=756067. Accessed October 29. 2021.


38. Robinson, L. Rapid test study could help doc- tors determine who needs COVID-19 booster shot. WBALTV11. Updated: August 19, 2021. https://www. wbaltv.com/article/rapid-test-study-covid-19- booster-shot/37351507#. Accessed October 29, 2021.


Jared Gresh, MT(ASCP) is a Technical Implementation Specialist at LumiraDx. He is a graduate of the medical technology program at Salve Regina University,


Brian K. DuChateau, PhD, D(ABMLI) is a board-certified clinical laboratory immunologist who received his PhD in immunology and medical microbiol- ogy from the University of


Wisconsin-Madison and completed a


post-doctoral residency in clinical immunology at the Chicago Medical School. With more than 20 years of experience as a clinical laboratory director and 12 years of in vitro diagnostics (IVD) experience, he currently serves as the LumiraDx Vice President of U.S. Scientific and Clinical Affairs.


14 DECEMBER 2021 MLO-ONLINE.COM


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54